Vanguard Portfolio Management
HUMA icon

Vanguard Portfolio Management’s Humacyte HUMA Stock Holding History

Vanguard Portfolio Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$443K Sell
568,521
-849,304
-60% -$787K ﹤0.01% 3065
2026
Q1 		$861K Buy
+1,417,825
New +$1.47M ﹤0.01% 2846

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management's HUMA Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Humacyte (HUMA) stake by 60% in Q2 2026, selling an estimated $787K and leaving 568,521 shares worth $443K. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Vanguard Portfolio Management first reported a position in HUMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $861K in Q1 2026. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Vanguard Portfolio Management held 568,521 shares of Humacyte worth $443K as of Q2 2026.
  • Vanguard Portfolio Management sold 849,304 Humacyte shares in Q2 2026, an estimated $787K.
  • Humacyte made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #3065 holding.
  • Vanguard Portfolio Management first reported a position in Humacyte in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Humacyte position peaked at $861K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.